Dicerna Pharmaceuticals Inc.

37.51+0.3600+0.97%Vol 406.27K1Y Perf 67.41%
Jul 30th, 2021 16:00 DELAYED
BID37.51 ASK37.52
Open37.10 Previous Close37.15
Pre-Market- After-Market37.51
 - -  - -%
Target Price
43.50 
Analyst Rating
Strong Buy 1.09
Potential %
15.97 
Finscreener Ranking
★★     46.75
Insiders Trans % 3/6/12 mo.
-100/-100/-98 
Value Ranking
★+     43.87
Insiders Value % 3/6/12 mo.
-100/-100/-99 
Growth Ranking
★★     46.29
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-99 
Income Ranking
 —    -
Market Cap2.88B 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
88.87 
Earnings Date
5th Aug 2021

Today's Price Range

37.1037.92

52W Range

16.5040.14

5 Year PE Ratio Range

-6.70-3.60

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
0.00%
1 Month
0.51%
3 Months
20.26%
6 Months
66.93%
1 Year
67.41%
3 Years
197.70%
5 Years
1 068.54%
10 Years
-

TickerPriceChg.Chg.%
DRNA37.510.36000.97
AAPL145.860.22000.15
GOOG2 704.42-26.3900-0.97
MSFT284.91-1.5900-0.55
XOM57.57-1.3600-2.31
WFC45.94-0.5600-1.20
JNJ172.200.02000.01
FB356.30-2.0200-0.56
GE12.95-0.3400-2.56
JPM151.78-1.2200-0.80
Financial StrengthValueIndustryS&P 500US Markets
3.20
3.30
0.27
0.41
-6 010.00
Leverage Ratio 5.30
ProfitabilityValueIndustryS&P 500US Markets
-
-67.60
-66.20
-4 964.50
-63.88
RevenueValueIndustryS&P 500US Markets
137.43M
1.79
207.92
285.29
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.28-0.39-39.29
Q04 20200.11-0.49-545.45
Q03 2020-0.17-0.29-70.59
Q02 20200.21-0.43-304.76
Q01 20200.28-0.31-210.71
Q04 2019-0.08-0.58-625.00
Q03 2019-0.30-0.45-50.00
Q02 2019-0.32-0.35-9.38
Earnings Per EndEstimateRevision %Trend
6/2021 QR0.5141.67Positive
9/2021 QR-0.24-9.09Negative
12/2021 FY-0.7417.78Positive
12/2022 FY-1.12-3.70Negative
Next Report Date5th Aug 2021
Estimated EPS Next Report0.51
Estimates Count6
EPS Growth Next 5 Years %-
Volume Overview
Volume406.27K
Shares Outstanding76.90M
Trades Count5.12K
Dollar Volume40.62M
Avg. Volume766.13K
Avg. Weekly Volume422.57K
Avg. Monthly Volume691.56K
Avg. Quarterly Volume720.91K

Dicerna Pharmaceuticals Inc. (NASDAQ: DRNA) stock closed at 37.51 per share at the end of the most recent trading day (a 0.97% change compared to the prior day closing price) with a volume of 406.97K shares and market capitalization of 2.88B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 302 people. Dicerna Pharmaceuticals Inc. CEO is Douglas M. Fambrough.

The one-year performance of Dicerna Pharmaceuticals Inc. stock is 67.41%, while year-to-date (YTD) performance is 70.27%. DRNA stock has a five-year performance of 1068.54%. Its 52-week range is between 16.5 and 40.14, which gives DRNA stock a 52-week price range ratio of 88.87%

Dicerna Pharmaceuticals Inc. currently has a PE ratio of -23.40, a price-to-book (PB) ratio of 22.82, a price-to-sale (PS) ratio of 20.69, a price to cashflow ratio of 10.90, a PEG ratio of 2.32, a ROA of -15.90%, a ROC of -65.26% and a ROE of -76.17%. The company’s profit margin is -63.88%, its EBITDA margin is -66.20%, and its revenue ttm is $137.43 Million , which makes it $1.79 revenue per share.

Of the last four earnings reports from Dicerna Pharmaceuticals Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $0.51 for the next earnings report. Dicerna Pharmaceuticals Inc.’s next earnings report date is 05th Aug 2021.

The consensus rating of Wall Street analysts for Dicerna Pharmaceuticals Inc. is Strong Buy (1.09), with a target price of $43.5, which is +15.97% compared to the current price. The earnings rating for Dicerna Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Dicerna Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Dicerna Pharmaceuticals Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 11.28, ATR14 : 1.70, CCI20 : -44.28, Chaikin Money Flow : 0.15, MACD : 0.43, Money Flow Index : 52.89, ROC : -3.52, RSI : 52.34, STOCH (14,3) : 46.87, STOCH RSI : 0.69, UO : 46.59, Williams %R : -53.13), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Dicerna Pharmaceuticals Inc. in the last 12-months were: Adam M. Koppel (Option Excercise at a value of $0), Adam M. Koppel (Sold 1 000 000 shares of value $23 400 000 ), Anna Protopapas (Option Excercise at a value of $0), Bob Brown (Option Excercise at a value of $1 157 201), Bob Brown (Sold 196 656 shares of value $5 104 847 ), Bob D. Brown (Option Excercise at a value of $870 300), Bob D. Brown (Sold 158 235 shares of value $4 369 578 ), Cynthia Smith (Option Excercise at a value of $0), Douglas M. Fambrough (Buy at a value of $180 597), Douglas M. Fambrough (Option Excercise at a value of $0), Douglas W. Pagan (Option Excercise at a value of $0), J. Kevin Buchi (Option Excercise at a value of $0), James B. Weissman (Option Excercise at a value of $388 176), James B. Weissman (Sold 77 828 shares of value $2 317 278 ), Marc Kozin (Option Excercise at a value of $0), Martin Freed (Option Excercise at a value of $0), Patrick M. Gray (Option Excercise at a value of $0), Regina M. Paglia (Option Excercise at a value of $1 723 888), Regina M. Paglia (Sold 103 144 shares of value $3 282 098 ), Robert D. Ciappenelli (Option Excercise at a value of $468 300), Robert D. Ciappenelli (Sold 30 000 shares of value $1 110 000 ), Stephen J. Hoffman (Option Excercise at a value of $0), Stephen K. Doberstein (Option Excercise at a value of $0)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
10 (90.91 %)
10 (90.91 %)
9 (100.00 %)
Moderate Buy
1 (9.09 %)
1 (9.09 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.09
Strong Buy
1.09
Strong Buy
1.00

Dicerna Pharmaceuticals Inc.

Dicerna Pharmaceuticals Inc is a biotechnology company involved in the discovery and development of innovative treatments for rare inherited diseases affecting the liver, along with cancers, and other therapeutic areas to address liver problems. The company is using ribonucleic acid interference (RNA) technology platform to develop its products. The product candidates are DCR-PHXC (for primary hyperoxaluria), DCR-undisclosed (for orphan genetic disease), DCR-PCSK9 (for cardiovascular disease), and DCR-HBV (for hepatitis B virus) among others.

CEO: Douglas M. Fambrough

Telephone: +1 617 621-8097

Address: 33 Hayden Avenue, Lexington 02421, MA, US

Number of employees: 302

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

100%0%

Bearish Bullish

52%48%

Bearish Bullish

60%40%

News

Stocktwits